A bibliometric and visualization analysis of research trends and hotspots on targeted therapy for breast cancer from 2003 to 2022

被引:5
作者
Wu, Deqi [1 ]
Pan, Chi [2 ]
Hu, Yangying [1 ]
Shi, Zhijie [1 ]
Zhou, Yankun [3 ]
Xiao, Min [4 ]
机构
[1] Zhejiang Shuren Univ, Shulan Hangzhou Hosp, Shulan Int Med Coll, Dept Thyroid & Breast Diag & Treatment Ctr, Hangzhou, Peoples R China
[2] Zhejiang Univ, Sch Med, Affiliated Hosp 2, Dept Breast Surg, Hangzhou, Peoples R China
[3] Zhejiang Univ, Sch Med, Hangzhou, Peoples R China
[4] Zhejiang Shuren Univ, Shulan Hangzhou Hosp, Shulan Int Med Coll, Dept Surg, Hangzhou, Peoples R China
关键词
breast cancer; targeted therapy; bibliometric analysis; Web of Science; trends; hotspots; VOSviewer; CiteSpace; PLUS ADJUVANT CHEMOTHERAPY; TRASTUZUMAB DERUXTECAN; OPEN-LABEL; RESISTANCE; SURVIVAL; COMBINATION; PROGRESSION; EVEROLIMUS; INHIBITORS; RIBOCICLIB;
D O I
10.3389/fonc.2024.1366900
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background Breast cancer is a significant public health issue, exhibiting the most pronounced occurrence and fatality rates among malignant neoplasms globally. Targeted therapy is a medical intervention that focuses on specific molecular markers. This study aims to investigate and evaluate the current research trends and directions in the field of targeted therapy for breast cancer using bibliometric analysis. Method The Web of Science database was utilized to retrieve relevant articles published between 2003 and 2022. The VOSviewer software and Bibliometrix package in the R language were employed to conduct co-occurrence and clustering analyses of authors, countries, institutions, journals, references, and the CiteSpace tool was utilized for keyword burst detection. Results A total of 2,258 articles were included and the annual number of publications increased rapidly. The most prolific country on this topic was the USA (n=898, 39.77%) and the University of Texas MD Anderson Cancer Center published most papers (n=93). Dennis J. Slamon and Gabriel N. Hortobagyi stood out in the field, with Dennis J. Slamon leading in terms of co-citations(n=653) and Gabriel N. Hortobagyi topping the list in terms of published articles(n=18). The most productive journal was Breast Cancer Research and Treatment and the most cited journal was Journal of Clinical Oncology. The clustering of keywords indicated that the primary focus of researches in the past two decades was on the development and clinical evaluation of tumor-targeted drugs associated with the epidermal growth factor receptor (EGFR) family signaling pathway, and explored mechanisms related to biological behavior of breast cancer. Keywords co-occurrence and burst analysis identified current research hotspots and potential research trends. Conclusion This study employed bibliometric analysis to examine research on targeted therapy for breast cancer over a span of 20 years, and identified development trends of research and elucidated potential research trajectories in the domain of this topic. This study helps in the identification of prospective collaborators and partner institutions for researchers.
引用
收藏
页数:17
相关论文
共 73 条
[1]   Targeting HER2-AXL heterodimerization to overcome resistance to HER2 blockade in breast cancer [J].
Adam-Artigues, Anna ;
Arenas, Enrique J. ;
Martinez-Sabadell, Alex ;
Braso-Maristany, Fara ;
Cervera, Raimundo ;
Tormo, Eduardo ;
Hernando, Cristina ;
Teresa Martinez, Maria ;
Carbonell-Asins, Juan ;
Simon, Soraya ;
Poveda, Jesus ;
Moragon, Santiago ;
Zazo, Sandra ;
Martinez, Debora ;
Rovira, Ana ;
Burgues, Octavio ;
Rojo, Federico ;
Albanell, Joan ;
Bermejo, Begona ;
Lluch, Ana ;
Prat, Aleix ;
Arribas, Joaquin ;
Eroles, Pilar ;
Miguel Cejalvo, Juan .
SCIENCE ADVANCES, 2022, 8 (20)
[2]   bibliometrix: An R-tool for comprehensive science mapping analysis [J].
Aria, Massimo ;
Cuccurullo, Corrado .
JOURNAL OF INFORMETRICS, 2017, 11 (04) :959-975
[3]   Randomized Phase II Trial of Everolimus in Combination With Tamoxifen in Patients With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer With Prior Exposure to Aromatase Inhibitors: A GINECO Study [J].
Bachelot, Thomas ;
Bourgier, Celine ;
Cropet, Claire ;
Ray-Coquard, Isabelle ;
Ferrero, Jean-Marc ;
Freyer, Gilles ;
Abadie-Lacourtoisie, Sophie ;
Eymard, Jean-Christophe ;
Debled, Marc ;
Spaeth, Dominique ;
Legouffe, Eric ;
Allouache, Djelila ;
El Kouri, Claude ;
Pujade-Lauraine, Eric .
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (22) :2718-2724
[4]   Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer [J].
Bardia, A. ;
Hurvitz, S. A. ;
Tolaney, S. M. ;
Loirat, D. ;
Punie, K. ;
Oliveira, M. ;
Brufsky, A. ;
Sardesai, S. D. ;
Kalinsky, K. ;
Zelnak, A. B. ;
Weaver, R. ;
Traina, T. ;
Dalenc, F. ;
Aftimos, P. ;
Lynce, F. ;
Diab, S. ;
Cortes, J. ;
O'Shaughnessy, J. ;
Dieras, V ;
Ferrario, C. ;
Schmid, P. ;
Carey, L. A. ;
Gianni, L. ;
Piccart, M. J. ;
Loibl, S. ;
Goldenberg, D. M. ;
Hong, Q. ;
Olivo, M. S. ;
Itri, L. M. ;
Rugo, H. S. .
NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (16) :1529-1541
[5]   The PI3 kinase/mTOR blocker NVP-BEZ235 overrides resistance against irreversible ErbB inhibitors in breast cancer cells [J].
Bruenner-Kubath, Caroline ;
Shabbir, Waheed ;
Saferding, Victoria ;
Wagner, Renate ;
Singer, Christian F. ;
Valent, Peter ;
Berger, Walter ;
Marian, Brigitte ;
Zielinski, Christoph C. ;
Grusch, Michael ;
Grunt, Thomas W. .
BREAST CANCER RESEARCH AND TREATMENT, 2011, 129 (02) :387-400
[6]   Comprehensive Genomic Analysis Identifies Novel Subtypes and Targets of Triple-Negative Breast Cancer [J].
Burstein, Matthew D. ;
Tsimelzon, Anna ;
Poage, Graham M. ;
Coyington, Kyle R. ;
Contreras, Alejandro ;
Fuqua, Suzanne A. W. ;
Sayage, Michelle I. ;
Osborne, C. Kent ;
Hilsenbeck, Susan G. ;
Chang, Jenny C. ;
Mills, Gordon B. ;
Lau, Ching C. ;
Brown, Powel H. .
CLINICAL CANCER RESEARCH, 2015, 21 (07) :1688-1698
[7]   Detachable Liposomes Combined Immunochemotherapy for Enhanced Triple-Negative Breast Cancer Treatment through Reprogramming of Tumor-Associated Macrophages [J].
Chen, Mingshu ;
Miao, Yunqiu ;
Qian, Kun ;
Zhou, Xin ;
Guo, Linmiao ;
Qiu, Yu ;
Wang, Rui ;
Gan, Yong ;
Zhang, Xinxin .
NANO LETTERS, 2021, 21 (14) :6031-6041
[8]   Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer [J].
Cortes, J. ;
Kim, S. -B ;
Chung, W. -P ;
Im, S. -A ;
Park, Y. H. ;
Hegg, R. ;
Kim, M. H. ;
Tseng, L. -M ;
Petry, V ;
Chung, C. -F ;
Iwata, H. ;
Hamilton, E. ;
Curigliano, G. ;
Xu, B. ;
Huang, C. -S ;
Kim, J. H. ;
Chiu, J. W. Y. ;
Pedrini, J. L. ;
Lee, C. ;
Liu, Y. ;
Cathcart, J. ;
Bako, E. ;
Verma, S. ;
Hurvitz, S. A. .
NEW ENGLAND JOURNAL OF MEDICINE, 2022, 386 (12) :1143-1154
[9]   Triple-negative breast cancer: Clinical features and patterns of recurrence [J].
Dent, Rebecca ;
Trudeau, Maureen ;
Pritchard, Kathleen I. ;
Hanna, Wedad M. ;
Kahn, Harriet K. ;
Sawka, Carol A. ;
Lickley, Lavina A. ;
Rawlinson, Ellen ;
Sun, Ping ;
Narod, Steven A. .
CLINICAL CANCER RESEARCH, 2007, 13 (15) :4429-4434
[10]   Overcoming trastuzumab resistance in HER2-positive breast cancer using combination therapy [J].
Derakhshani, Afshin ;
Rezaei, Zohreh ;
Safarpour, Hossein ;
Sabri, Morteza ;
Mir, Atefeh ;
Sanati, Mohammad Amin ;
Vahidian, Fatemeh ;
Moghadam, Ali Gholamiyan ;
Aghadoukht, Ali ;
Hajiasgharzadeh, Khalil ;
Baradaran, Behzad .
JOURNAL OF CELLULAR PHYSIOLOGY, 2020, 235 (04) :3142-3156